Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Haemonetics Corporation on June 5, 2026. The report discloses a strategic change to the company's reportable segment structure effective for the first quarter of fiscal 2027.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on organizational restructuring and reporting methodology.
Material Changes
- Segment Restructuring: The previously reported "Plasma" and "Blood Center" segments will be combined into a single reportable segment named "Apheresis."
- Renaming: The "Hospital" segment will be renamed "MedSurg."
- Rationale: These changes are intended to better align external financial reporting with how management operates the business and allocates resources.
- Historical Recasting: The company has provided quarterly historical reconciliations from Q1 fiscal 2024 through Q4 fiscal 2026 on its Investor Relations website.
Guidance, Outlook, and Management Commentary
- Guidance Status: The company has provided a recast of its previously issued fiscal 2027 guidance to reflect the new segment structure.
- Reaffirmation: The company is not reaffirming or updating its fiscal 2027 guidance in this filing.
- Future Updates: Any updates to guidance will be provided during the first quarter fiscal 2027 earnings call.
Investor Verification Checklist
- Verify the historical financial reconciliations posted on the Haemonetics Investor Relations website.
- Review the recast fiscal 2027 guidance to understand the impact of the new segment definitions.
- Monitor the upcoming first quarter fiscal 2027 earnings call for any updated financial outlook.
- Confirm the specific operational definitions of the new "Apheresis" and "MedSurg" segments in the supplemental presentation.